Dalbavancin: a novel antimicrobial.
The increasing incidence of serious infections because of Gram-positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram-positive pathogens. A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1-2 doses of dalbavancin vs. linezolid. The results demonstrated non-inferiority and a comparable safety profile. With its unique pharmacokinetic profile, ease of use and excellent safety profile, dalbavancin should provide a valuable addition to the armamentarium used to treat infections because of Gram-positive cocci.
Chen
A Y
AY
Wayne State University School of Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI 48202, USA.
Zervos
M J
MJ
Vazquez
J A
JA
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D012107:Research Design; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017334:Teicoplanin; C469289:dalbavancin